Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 13/20 | 0.52 |
| ▸ | HSP90AB1 | P08238 | 13/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 4/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13627493 | 0.89 | HSP90AA1 (0.66) | HSP90AA1HSP90AB1ALDH1A1MAPT | |
| SCHEMBL13627517 | 0.87 | HSP90AA1 (0.53) | HSP90AA1HSP90AB1 | |
| SCHEMBL13627511 | 0.83 | HSP90AA1 (0.48) | HSP90AA1HSP90AB1ALDH1A1GAAMAPT | |
| SCHEMBL13627516 | 0.83 | HSP90AA1 (0.48) | HSP90AA1HSP90AB1 | |
| SCHEMBL13627468 | 0.82 | HSP90AA1 (0.63) | HSP90AA1HSP90AB1 | |
| SCHEMBL13627510 | 0.81 | MAPT (0.52) | HSP90AA1HSP90AB1ALDH1A1SMN1; SMN2GFER | |
| SCHEMBL4494977 | 0.81 | HSP90AA1 (0.47) | HSP90AA1HSP90AB1 | |
| SCHEMBL13627505 | 0.80 | HSP90AA1 (0.48) | HSP90AA1HSP90AB1 | |
| SCHEMBL4484388 | 0.80 | BACE1 (0.43) | HSP90AA1HSP90AB1ALDH1A1SMN1; SMN2GAA | |
| SCHEMBL13627491 | 0.79 | HSP90AA1 (0.65) | HSP90AA1HSP90AB1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612201-B2 | Pyrazole compounds | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2009-11-03 | — | — | US | disclosed |
| US-7612201-B2 | Pyrazole compounds | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2009-11-03 | — | — | US | disclosed |
| US-7612201-B2 | Pyrazole compounds | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2009-11-03 | — | — | US | disclosed |
| US-20060148817-A1 | Pyrazole compounds | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2006-07-06 | — | — | US | disclosed |
| EP-1572664-A1 | PYRAZOLE COMPOUNDS | Vernalis (Cambridge) Limited (GB) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004056782-A1 | PYRAZOLE COMPOUNDS | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148817-A1 | Pyrazole compounds | NRAS, HSP90AB1, HSP90AA1 | HSP90AA1 3/4885HSP90AB1 2/4885ALDH1A1 883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.